ArticleMolecular therapy. Advances2026
Case study of resecabtagene autoleucel in a subject with diffuse cutaneous systemic sclerosis treated in the RESET-SSc trial.
Article in Molecular therapy. Advances, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06328777 (A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells), which is not on this map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1/2, Open-Label Study to Evaluate the Safety and Efficacy of Autologous CD19-specific Chimeric Antigen Receptor T Cells (CABA-201) in Subjects With Systemic Sclerosis
Who cites it
2 citing papers in PubMed.
- Trial
- CD19 CAR T cell therapy in systemic sclerosis: A case study that reaffirms the promise of cell therapy to treat autoimmune disease.Molecular therapy. Advances · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
34 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Under compassionate use, CAR T cells have elicited durable remissions in patients with refractory systemic sclerosis (SSc). Here, we report on the safety, efficacy, and correlative data of the first SSc subject treated with a fully human CD19-CART cell therapy (resecabtagene autoleucel) in the RESET-SSc trial (NCT06328777). Nine days post-infusion, the subject experienced a brief grade 2 episode of cytokine release syndrome that resolved promptly with intravenous hydration and indomethacin. Immune-effector-cell-associated neurotoxicity syndrome was not observed. Seven days post-infusion, the subject experienced a brief grade 4 episode of neutropenia that resolved rapidly with a single dose of colony-stimulating factor. Despite discontinuation of all immunosuppressants since infusion, over the 9-month period post-infusion, the subject's skin thickness decreased, pulmonary function improved, and nailfold vasculature improvement was observed. Following infusion, B cells were depleted both in the periphery and within secondary lymphoid tissue. B cell aplasia was observed by day 13 post-infusion. Furthermore, serum BAFF was highly elevated. B cell repopulation began 8 weeks post-infusion, with cells exhibiting a transitional naive phenotype. Autoantibodies to RNA polymerase III decreased to undetectable levels. The infusion product consisted of predominantly CD4
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.